Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...

On Friday, BioNTech SE (NASDAQ:BNTX) and its partner Duality Biologics (Suzhou) Co., Ltd. released topline data from a Phase 3 trial in China evaluating trastuzumab pamirtecan (BNT323/DB-1303) versus ...

In this video, Paolo Tarantino, MD, PhD, an advanced fellow at Dana-Farber Cancer Institute, discusses the pros and cons of trastuzumab deruxtecan in neoadjuvant and adjuvant settings.Tarantino said a ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Roche’s blockbuster breast cancer treatment Herceptin will face more competition after Pfizer’s biosimilar won FDA approval March 11, according to Reuters. The FDA has already approved biosimilar ...

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

For the best experience, please enable JavaScript in your browser settings. Herceptin drug has been identified as counterfeit. [MoH] The Pharmacy and Poisons Board ...

The Pharmacy and Poisons Board (PPB) has cautioned the public against the use, sale, or distribution of Herceptin (Trastuzumab 440mg), circulating in the Kenyan market. Herceptin is a drug used to ...